Though tin metal is very poorly absorbed, tin compounds may be absorbed via oral, inhalation, or dermal routes, with organotin compounds being much more readily absorbed than inorganic tin compounds. Tin may enter the bloodstream and bind to hemoglobin, where it is distributed and accumulates mainly in the kidney, liver, lung, and bone. Organotin compounds may undergo dealkylation, hydroxylation, dearylation, and oxidation catalyzed by cytochrome P-450 enzymes in the liver. The alkyl products of dealkylation are conjugated with glutathione and further metabolized to mercapturic acid derivatives. Tin and its metabolites are excreted mainly in the urine and feces. (L308)
Organotin compounds produce neurotoxic and immunotoxic effects. Organotins may directly activate glial cells contributing to neuronal cell degeneration by local release of pro-inflammatory cytokines, tumor necrosis factor-_, and/or interleukins. They may also induce apoptosis by direct action on neuronal cells. Organotin compounds stimulate the neuronal release of and/or decrease of neuronal cell uptake of neurotransmitters in brain tissue, including aspartate, GABA, glutamate, norepinephrine, and serotonin. This may be either a contributing factor to or result of the neuronal cell loss. The immunotoxic effects of organotins are characterized by thymic atrophy caused by the suppression of proliferation of immature thymocytes and apoptosis of mature thymocytes. Organotin compounds are believed to exert these effects by suppressing DNA and protein synthesis, inducing the expression of genes involved in apoptosis (such as nur77), and disrupting the regulation of intracellular calcium levels, giving rise to the uncontrolled production of reactive oxygen species, release of cytochrome c to the cytosol, and the proteolytic and nucleolytic cascade of apoptosis. The suppression of proliferation of immature thymocytes further results in the suppression of T-cell-mediated immune responses. Organotins are also endocrine disruptors and are believed to contribute to obesity by inappropriate receptor activation, leading to adipocyte differentiation. Inorganic tin triggers eryptosis, contributing to tin-induced anemia. (L308, A182, A184)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
致癌物分类
对人类不具有致癌性(未被国际癌症研究机构IARC列名)。
No indication of carcinogenicity to humans (not listed by IARC).
Breathing or swallowing, or skin contact with organotins, can interfere with the way the brain and nervous system work, causing death in severe cases. Organic tin compounds may also damage the immune and reproductive system. (L307, L308)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
暴露途径
口服(L308);吸入(L308);皮肤给药(L308)
Oral (L308) ; inhalation (L308) ; dermal (L308)
来源:Toxin and Toxin Target Database (T3DB)
毒理性
症状
无机或有机锡化合物放置在皮肤上或进入眼睛中可能会引起皮肤和眼睛的刺激。
Inorganic or organic tin compounds placed on the skin or in the eyes can produce skin and eye irritation. (L308)
A method for the synthesis of a first organic molecule, said method comprising the steps of:
a) Reacting a first reactant with an organotin reactant having at least one organic group having from 5 to 20 carbon atoms selected from alkyl, alkoxyalkyl, alkoxy, alkylthioalkyl, carboxylates and alkylaminoalkyl groups, thereby forming a mixture of a product and a tin-containing by-product, and
b) Removing most of the tin-containing by-product from said mixture in such a way as to provide a purified product comprising less than 1000 ppm of remaining tin-containing by-product, wherein said step of removing most of said tin-containing by-product is either an extraction between a first liquid being an alkane or a mixture of alkanes having from 5 to 17 carbon atoms and a second liquid more polar than said first liquid or is a reversed phase chromatography.
Anion Selectivity of Tetravalent Tin Compounds in Membranes Studied by119Sn-,13C- and1H-NMR
作者:Hung-Viet Pham、Ern� Pretsch、Karl Fluri、Andras Bezegh、Wilhelm Simon
DOI:10.1002/hlca.19900730712
日期:1990.10.31
trialkyltin compounds of the type R3SnY have been investigated in view of their applicability as ion-selective components in solvent polymeric membranes. The interaction between these compounds and anions has been studied using 119Sn- and 13C-NMR. Neutral tetracoordinated trialkyltin compounds form a negatively charged pentacoordinated complex upon interaction with Cl-ions in homogeneous organic phases
考虑到R 3 SnY型三烷基锡化合物作为离子选择性组分在溶剂聚合物膜中的适用性,已经研究了其基本的分子方面。这些化合物与阴离子之间的相互作用已使用119 Sn -NMR和13 C-NMR进行了研究。中性四配位三烷基锡化合物在均相有机相以及与水溶液接触的膜中与Cl离子相互作用时形成带负电荷的五配位络合物。尽管在均相中,负电取代基Y决定了络合物的形成常数,但它对含有三烷基锡载体R 3的液膜中的电位阴离子选择性没有影响。具有不同Y的SnY。观察到的选择性模式不是由均匀相中的稳定常数的大小决定的,而是由普遍的缔合-解离过程决定的,该过程导致四配位化合物由于样品组成的变化而组成发生变化,获得的结果在均相和两相系统中对四价单锡化合物与阴离子的平衡研究的结果证实了较早的假设,即溶剂聚合物膜中掺入的三烷基锡化合物充当阴离子的电中性载体。
Method for producing tetrazolylbenzene compound
申请人:Takeda Chemical Industries, Ltd.
公开号:US05599943A1
公开(公告)日:1997-02-04
Disclosed are a compound of the formula (R).sub.3 SnN.sub.3, wherein R is a C.sub.7-18 alkyl, and a process for producing a tetrazolylbenzene compound which comprises reacting a cyanobenzene compound with a (R).sub.3 SnN.sub.3. This process is useful for a safe and commercially profitable production of the tetrazolylbenzene compound which is employed for producing a tetrazole derivative having a hypotensive action based on angiotensin II-antagonizing activity or a production intermediate thereof.
A process for producing crystals of 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimdazole-7-carboxylic acid (compound (I)), characterized by dissolving or suspending the compound (I) or a salt thereof in a solvent comprising an aprotic polar solvent and crystallizing it. By the process, the contaminants which are contained in the compound (I) or its salt and are difficult to remove, such as tin compounds, analogues of the compound (I), and a residual organic solvent, can be easily removed. Crystals of the compound (I) can be efficiently and easily mass-produced in high yield on an industrial scale.
Disclosed are a compound of the formula (R).sub.3 SnN.sub.3, wherein R is a C.sub.7-18 alkyl, and a process for producing a tetrazolylbenzene compound which comprises reacting a cyanobenzene compound with a (R).sub.3 SnN.sub.3. This process is useful for a safe and commercially profitable production of the tetrazolylbenzene compound which is employed for producing a tetrazole derivative having a hypotensive action based on angiotensin II-antagonizing activity or a production intermediate thereof.